Finch Therapeutics Group, Inc. (FNCH)

2,7800 +0,0600 (+2,21%) A partir del 11:05AM EDT. Mercado abierto.

Finch Therapeutics Group, Inc.

200 Inner Belt Road
Suite 400
Somerville, MA 02143
United States
617 229 6499
https://www.finchtherapeutics.com

Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 189

Ejecutivos clave

Nombre	Título	Paga	Ejecutado	Año de nacimiento
Dr. Mark Burnham Smith Ph.D.	CEO & Director	698,66k	N/A	1987
Mr. Marc B. Blaustein C.F.A., CFA, MPP	COO, Principal Financial & Accounting Officer	378,21k	N/A	1963
Mr. Joseph D. Vittiglio Esq., J.D.	Chief Bus. & Legal Officer and Corp. Sec.	526,08k	N/A	1972
Mr. Bryan Gillis M.B.A.	Chief Technology Officer	N/A	N/A	N/A
Mr. James S. Sigler	Exec. VP of CMC	N/A	N/A	1961
Ms. Sonia Timberlake	Sr. VP of Research	N/A	N/A	N/A
Dr. Howard Franklin M.B.A., M.D.	Interim Chief Medical Officer	N/A	N/A	N/A
Dr. Alka Batycky Ph.D.	Chief Devel. Officer	N/A	N/A	N/A

Los importes son a partir de 31 de diciembre de 2021 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company's lead candidate is CP101, an orally administered microbiome capsule that is in Phase 3 clinical trial for the treatment of patients with recurrent Clostridioides difficile infection, as well as for the treatment of chronic hepatitis B virus. It is also developing FIN-211, an orally administered enriched consortia product candidate for use in the treatment of autism spectrum disorder; and TAK-524 and FIN-525, which are orally administered targeted consortia product candidates for the treatment of ulcerative colitis and Crohn's disease. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; Skysong Innovations LLC; and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Somerville, Massachusetts.

Gobierno corporativo

El ISS Governance QualityScore de Finch Therapeutics Group, Inc., a día N/A, es N/A. Las puntuaciones base son Auditoría: N/A; Tablero: N/A; Derechos de los accionistas: N/A; Compensación: N/A.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.